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Abstract
Enteropathogenic E. coli (EPEC) is a human pathogen that causes acute and chronic pedi-
atric diarrhea. The hallmark of EPEC infection is the formation of attaching and effacing (A/
E) lesions in the intestinal epithelium. Formation of A/E lesions is mediated by genes located
on the pathogenicity island locus of enterocyte effacement (LEE), which encode the adhesin
intimin, a type III secretion system (T3SS) and six effectors, including the essential translo-
cated intimin receptor (Tir). Seventeen additional effectors are encoded by genes located
outside the LEE, in insertion elements and prophages. Here, using a stepwise approach, we
generated an EPEC mutant lacking the entire effector genes (EPEC0) and intermediate
mutants. We show that EPEC0 contains a functional T3SS. An EPEC mutant expressing
intimin but lacking all the LEE effectors but Tir (EPEC1) was able to trigger robust actin poly-
merization in HeLa cells and mucin-producing intestinal LS174T cells. However, EPEC1
was unable to form A/E lesions on human intestinal in vitro organ cultures (IVOC). Screen-
ing the intermediate mutants for genes involved in A/E lesion formation on IVOC revealed
that strains lacking non-LEE effector/s have a marginal ability to form A/E lesions. Further-
more, we found that Efa1/LifA proteins are important for A/E lesion formation efficiency in
EPEC strains lacking multiple effectors. Taken together, these results demonstrate the intri-
cate relationships between T3SS effectors and the essential role non-LEE effectors play in
A/E lesion formation on mucosal surfaces.
Author summary
Enteropathogenic E. coli (EPEC) causes diarrhea and generates the attaching and effacing
(A/E) lesion in human gut epithelium. A/E lesion formation requires the locus of enterocyte
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effacement (LEE) in the bacterial genome, which encodes a protein injection system deliver-
ing the translocated intimin receptor (Tir), which binds to intimin on the bacterial surface.
Intimin-Tir interaction is sufficient for bacterial attachment to epithelial cells in vitro but
additional effectors may be needed for A/E lesion formation in the human gut. By generat-
ing deletion mutants lacking combinations or the whole repertoire of protein effectors
encoded by EPEC, we show that intimin-Tir interaction is not sufficient and reveal an addi-
tive role of non-LEE effectors for A/E lesion formation in human intestinal tissue.
Introduction
The gastrointestinal epithelium is an important defense barrier against infections [1]. Enteric
pathogens have acquired virulence traits that enable them to colonize and break this barrier,
by adhering to the epithelium, delivering toxins and invading intestinal epithelial cells. To this
end, several important human and animal pathogens employ type III secretion systems (T3SS)
to inject virulence factors into infected eukaryotic cells, where they take control of cell signal-
ing [2].
Enteropathogenic E. coli (EPEC) and enterohemorrahgic E. coli (EHEC) are important
human pathogens that colonize the gut mucosa through attaching and effacing (A/E) lesions
[3], characterized by intimate bacterial attachment to the apical plasma membrane, localized
accumulation of F-actin and effacement of the brush border microvilli [4]. The ability to
induce A/E lesions requires the pathogenicity island the locus of enterocyte effacement (LEE)
[5, 6]. The LEE encodes gene regulators, the adhesin intimin, chaperones, a filamentous T3SS
composed of the translocators proteins (EspA, EspB and EspD), and six effectors (Tir, EspF,
Map, EspG, EspH, and EspZ) [7]. In HeLa cells, clustering of intimin with its receptor Tir [8]
triggers robust actin polymerization leading to formation of pedestal-like structures [4, 9]. On
mucosal surfaces, intimin–Tir interaction is necessary for A/E lesion formation, but it is not
currently known if this binding is sufficient [10].
Most LEE effectors, except EspZ, are strong inducers of cytotoxicity, cytoskeleton reorgani-
zation, and electrolyte imbalance leading to diarrhea [11, 12]. Map functions as a Cdc42 GEF
(Guanine nucleotide exchange factor), leading to filopodia formation on HeLa cells within
minutes after infection [13, 14]; EspH inhibits the activity of endogenous DH-PH RhoGEFs
causing disassembly of focal adhesions (FAs) and cell detachment [15, 16] and EspG interferes
with recycling endosomes [17, 18]. EspZ, which like Tir integrates into the plasma membrane,
regulates effector translocation, thus protecting infected cells form cytotoxicity [19].
The prototype EPEC strain E2348/69 also contains 17 effector genes located in integrative
elements (IEs) and prophages (PPs). These effectors are frequently found in gene clusters, with
some effectors having duplicated gene copies and/or paralogs in different clusters [20]. A large
proportion of the non-LEE effectors (e.g. NleB, C, D, E, F and H) inhibits host inflammation
([e.g. nuclear factor kappa B (NF-κB); mitogen-activated protein kinase (MAPK) and the non-
canonical inflammasome] [12, 21, 22] and apoptosis (e.g. NleB, D and H) [23]. In particular,
NleC is a zinc metalloprotease that degrades the p65 subunit of NF-κB [24].
Deng et al. reported two additional non-LEE effectors, NleJ and LifA/Efa1 [25]. While
the function of NleJ is not known, LifA/Efa1, also called lymphostatin [26], has a putative gly-
cosyltransferase activity and an important role in intestinal colonization of cattle by EHEC
serogroup O5, O111, and O26 strains [27–29], as efa1 mutations dramatically reduced the
number of mucosal associated bacteria and fecal shedding. The reason for this apparent atten-
uation is not known.
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EPEC is a human restricted pathogen; for this reason human intestinal in vitro organ cul-
tures (IVOC) have been used to study early interactions of EPEC with mucosal surfaces [30–
33]. Following IVOC infection EPEC triggers A/E lesions that are indistinguishable from those
observed in intestinal biopsies of patients with EPEC diarrhea. Using this model it has been
shown that while intimin and Tir are essential for colonization, Tir tyrosine phosphorylation
is dispensable for A/E lesion formation [10]. However, this infection model has not yet been
used to investigate if intimin-Tir interaction is sufficient for A/E lesion formation. The aim of
our study is to determine whehter intimin-Tir interaction is sufficient for A/E lesion formation
in human IVOC identify further effector(s) required for their formation. To this end, we gen-
erated an effector-less mutant of E2348/69 strain and a library of intermediate deletion
mutants lacking effectors and preserving the correct assembly and function of the T3SS injecti-
some. This unveiled that EPEC mutants expressing only Tir were unable to produce A/E
lesions on IVOC, while able to produce typical actin pedestals on epithelial cells in vitro. In
addition, we found that an EPEC mutant lacking all the non-LEE effector genes shows a mar-
ginal ability to form A/E lesions on human intestinal IVOC.
Results
Generation of the effector mutant EPEC strains
We employed a marker-less deletion/replacement strategy to generate a library of EPEC effec-
tor mutants, which allow multiple deletions and/or integrations while leaving neither an anti-
biotic gene cassette nor short heterologous DNA sequences ("scars") in the chromosome [34].
The mutant alleles were designed to delete the coding sequences of effector genes from the
start to the stop codon, or in the case of gene clusters and operons, from the start codon of the
first open reading frame (ORF) to the stop codon of the last ORF, maintaining upstream and
downstream sequences containing endogenous regulatory elements (e.g. promoters, transcrip-
tional terminators) intact (S1 Fig). We first tested this marker-less deletion strategy by generat-
ing an EPEC mutant in escN, encoding the ATPase of the T3SS, whose deletion abrogated
secretion of EspA, EspB and EspD in DMEM, but not of EspC autotransporter (S2 Fig). Next,
we generated a set of suicide vectors (pGE and pGETS derivatives) for the deletion of all the
known effectors in E2348/69 (Table A of S1 Text) [20, 25].
We sequentially deleted LEE effector genes map, espG, espF and espH (Fig 1A) to obtain the
mutant strain called EPEC9 (Table 1). The LEE effectors espZ and tir were not deleted at this
stage, as EspZ, by regulating effector translocation, protects cells from cytotoxicity [19] and
Tir, by mediating intimate attachment, enhances protein translocation [35].
Next, we deleted the genes encoding the non-LEE effectors (Fig 1B). The order of deletion
followed was: IE5 (espG2 and espC), IE6 (espL, nleB1, nleE1, efa1/lifA) and IE2 (espL, nleB,
nleE2, efa1/lifA-like). Although EspC is not a T3SS effector, we deleted espC together with
espG2 in the IE5 because EspC has been reported to be internalized into the host cell in a
T3SS-dependent manner [36, 37], can interact with translocon proteins [38], and is known to
induce severe cytopathic effects and cell death on epithelial cells [39, 40]. The resulting effector
mutant strains were called EPEC8, EPEC7 and EPEC6, respectively (Table 1).
We continued by sequential deletion of the effector genes in PPs: PP2 (nleH1, cif, espJ),
PP3 (nleJ), PP4 (nleG, nleB, nleC, nleH, nleD) and PP6 (nleA/espI, nleH2, nleF, espO) (Fig 1B),
resulting in a strain we named EPEC2, which contains EspZ and Tir as the only effectors. We
then proceed with the deletion of espZ. However, we found that deletion of the coding
sequence of espZ (ΔespZ-1, S3A Fig), which is the first gene of the LEE2 operon, reduced the
secretion of the translocators (EspA, EspB and EspD) of the T3SS (S3B Fig). We speculated
that abortive translation initiation induced by the RBS of espZ could potentially affect
EPEC non-LEE effectors in A/E lesion formation
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translation of downstream genes in the LEE2 operon. Then, we generated a second mutant
allele of espZ that included deletion of its RBS, called ΔespZ-2 (S3A Fig), which did not affect
secretion of the translocators (S3B Fig). Using this mutant allele on EPEC2, we generated the
Fig 1. Deletion of effector genes in EPEC E2348/69. A. Representation of the LEE pathogenicity island. Effector genes are labeled in red. The
order of deletion is numbered: deletion 1, 2, 3, 4 are for map, espG, espF and espH respectively. The espZ and tir genes were deleted after the
non-LEE effectors, with order 12 and 13 respectively. Scale of 5 kb is indicated at the bottom. B. Effector genes located outside the LEE are
localized in integrative elements (IE) and prophages (PP). Effector genes are labeled in red. Pseudogenes are specified with asterisk. The red
bars indicate the deletions carried out. The order of deletion is numbered. Scale of 5 kb is indicated at the bottom.
https://doi.org/10.1371/journal.ppat.1006706.g001
EPEC non-LEE effectors in A/E lesion formation
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EPEC1 strain that only carries tir. Lastly, we deleted tir in EPEC1 generating the effector-less
strain EPEC0. The steps followed to delete T3 effectors in WT EPEC are summarized in
Table B of S1 Text.
During generation of each mutant strain, we confirmed the expected deletion by PCR
using specific primers (Table C). Confirmation of all deletions in EPEC0 is shown in S4 Fig.
In addition, we performed whole-genome sequencing of the parental WT EPEC and EPEC1.
Sequencing reads were assembled both using the reference genomes of EPEC E2349/69 and
the in silico designed sequence of EPEC1, as well as fully assembled de novo from the sequenc-
ing reads. Genome comparison between WT EPEC and EPEC1 showed that the only differ-
ences between both strains were the designed deletions (Table D in S1 Text).
The T3SS injectisome is functional in the EPEC effector mutants
WT EPEC and the effector mutants EPEC2, EPEC1 and EPEC0 showed identical growth and
viability at 37˚C in LB and DMEM media (S5A and S5B Fig, respectively). In addition, micro-
scopic analysis of bacteria from these cultures did not show changes in bacterial size or mor-
phology (S5C Fig). To test the functionality of the T3SS, we analyzed the proteins secreted by
Table 1. EPEC strains used in this work.
Strain Genotype and relevant properties Reference
E2348/69 Wild type EPEC O127:H6 [20]
EPECΔescN E2348/69 ΔescN This work
EPECΔmap E2348/69 Δmap This work
EPEC11 E2348/69 Δmap ΔespG This work
EPEC10 E2348/69 Δmap ΔespG ΔespF This work
EPEC9 E2348/69 Δmap ΔespG ΔespF ΔespH This work
EPEC8 EPEC9 ΔIE5 (espG2 espC) This work
EPEC7 EPEC8 ΔIE6 (espL, nleB1, nleE1, efa1/lifA) This work
EPEC6 EPEC7 ΔIE2 (espL*, nleB*, nleE2, efa1/lifA-like) This work
EPEC5 EPEC6 ΔPP2 (nleH1, cif*, espJ) This work
EPEC4 EPEC5 ΔPP3 (nleJ) This work
EPEC3 EPEC4 ΔPP4 (nleG, nleB, nleC, nleH*, nleD) This work
EPEC2 EPEC3 ΔPP6 (nleA/espI, nleH2, nleF, espO*) This work
EPEC1 EPEC2 ΔespZ-2 This work
EPEC0 EPEC1 Δtir This work
EPEC2Δeae EPEC2 Δeae This work
EPEC1Δeae EPEC1 Δeae This work
EPEC2map EPEC2 +map This work
EPEC1map EPEC1 +map This work
EPEC0map EPEC0 +map This work
EPEC2nleC EPEC2 +nleC This work
EPEC1nleC EPEC1 +nleC This work
EPEC0nleC EPEC0 +nleC This work
EPEC2LEE EPEC2 +map, +espH, +espF, +espG This work
EPEC7ΔlifA-like EPEC7 Δefa1/lifA-like This work
EPEC7ΔnleE2 EPEC7 ΔnleE2 This work
EPECΔlifA-like E2348/69ΔlifA-like This work
EPECΔlifA E2348/69ΔlifA This work
EPECΔlifA-likeΔlifA E2348/69ΔlifA-like ΔlifA This work
https://doi.org/10.1371/journal.ppat.1006706.t001
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WT EPEC, EPECΔescN (negative control), and the effector mutant EPEC strains, after 4 h
growth in DMEM at 37˚C. We found that the translocators EspA, EspB and EspD, which are
secreted by the T3SS [41], accumulated at roughly similar levels in the extracellular media of
cultures of WT EPEC and the effector mutant strains (Fig 2A, top panel), but not in the ΔescN
negative control. As expected, the autotransporter EspC was absent in the media of strains
with deletion of IE5 (from EPEC8 to EPEC0). The expression of the structural proteins EscC,
EscJ, EscD, and the translocator protein EspB, was evaluated by Western blotting in protein
extracts of whole bacteria from these cultures. All the effectors mutant strains showed equal
expression of the analyzed injectisome proteins compared to WT EPEC (Fig 2A, bottom pan-
els). Detection of cytoplasmic E. coli chaperonin GroEL was used as an internal loading con-
trol. Altogether, these experiments demonstrate that the effector mutant EPEC strains are not
affected in bacterial growth and express normal levels of T3SS injectisomes able to secrete the
translocators.
Tir translocation and actin pedestal formation in HeLa cells
We investigated whether the effector mutants were able to translocate Tir and trigger actin-
pedestal formation upon infection of cultured mammalian cells. HeLa cells were infected with
WT EPEC and the effector mutants for 1.5 h, fixed and stained for immunofluorescence
microscopy. All the effector mutant strains, but EPEC0, triggered actin polymerization upon
infection (Fig 2B) and form typical microcolonies, indicating the correct expression of bundle
forming pili (BFP) in these strains [42]. Quantification of the number of cells with actin pedes-
tals in these infections shows similar values for WT, EPEC2 and EPEC1, with no actin pedes-
tals found in EPEC0 (Fig 2C).
To confirm that actin accumulation induced by EPEC2 and EPEC1 was due to intimin-Tir
interaction we generated eae (encoding intimin) deletion mutants in both strains. Whereas
EPEC2Δeae and EPEC1Δeae secreted normal levels of T3SS translocators (S6A Fig), they did
not induce actin-pedestals in HeLa cells (S6B Fig). This demonstrates that the actin accumula-
tions observed in HeLa cells infected by EPEC2 and EPEC1 are actual actin-pedestals caused
by the specific intimin-mediated clustering of translocated Tir.
Quantification of protein translocation by the EPEC effector mutants
We quantified the protein translocation levels of the EPEC effector mutants in HeLa cells
using β-lactamase (Bla) fusions [43]. WT EPEC, EPEC2, EPEC1, EPEC0, and EPECΔescN as
negative control, were transformed with plasmid pEspF1-20-Bla, which encodes a fusion
between Bla and the N-terminal 20 amino acid signal of the EspF to drive its T3SS-dependent
translocation [43, 44]. WT EPEC harboring pCX340, encoding Bla without T3 signal, was used
as an additional negative control. Whereas no translocation was observed with the control
strains, no significant difference in the level of protein translocation was observed from WT
and EPEC-2 (Fig 2D). However, EPEC1, which is devoid of espZ, translocated higher levels of
EspF1-20-Bla than WT EPEC and EPEC2. Conversely, EPEC0, which lacks intimate adhesion,
translocate lower levels of Bla (Fig 2D). These observations are consistent with the reported
activities of EspZ and Tir [19, 35].
Translocation of specific effectors into HeLa cells by the EPEC effector
mutants
We investigated the phenotypes following translocation of selected effectors from the different
EPEC mutants. In order to maintain physiological expression levels, we integrated a single
copy of the effector gene of interest in its native chromosomal location. We followed the
EPEC non-LEE effectors in A/E lesion formation
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Fig 2. Functionality of T3SS of the EPEC effector mutants. A. Analysis of secreted and bacterial proteins
in the indicated EPEC strains after 4 h of growth in DMEM at 37˚C. Top panel: Coomassie staining of proteins
EPEC non-LEE effectors in A/E lesion formation
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marker-less strategy for gene integration, using suicide vectors with the effector gene and
flanking homology regions that preserve genome context and native regulatory elements (i.e.,
promoters, RBS, terminators). We integrated individually the effector genes map and nleC,
into the chromosome of EPEC2, EPEC1 and EPEC0 (Table 1).
We tested whether EPEC2, EPEC1 and EPEC0 expressing Map could produce filopodia
early during infection. Swiss 3T3 cells were infected for 10 min with EPEC2, EPEC1 and
EPEC0 and isogenic strains with an integrated copy of map. Actin staining of infected cells
revealed the induction of filopodia by the effector mutant EPEC strains carrying map in the
vast majority of infected cells, but not in cells infected by their parental strains (Fig 3). EPEC1
+map showed the strongest phenotype of filopodia formation, whereas EPEC0+map induced
the weakest phenotype.
We next tested whether EPEC2, EPEC1 and EPEC0 expressing NleC could degrade p65.
HeLa cells were infected for 4h with WT EPEC and effector mutant strains, with or without
reintegrated nleC. Western blots of the cell lysates with anti-p65 (N-terminal) antibodies
revealed that p65 was proteolysed in cells infected with all the EPEC strains expressing nleC
(Fig 4). Proteolysis of p65 in cells infected with the effector mutant strains carrying nleC was
higher than that induced by WT EPEC, likely caused by the presence of other effectors in
EPEC (e.g. NleE, NleB) that inhibit NF-kB activation and the release of free p65 subunit,
which is the preferential substrate of NleC [45–47]. Taken together, these results show that the
different strains in the effector mutant library contain a functional T3SS, thus allowing us to
employ them for infection of human intestinal IVOC.
Non-LEE effectors are needed for A/E lesion formation in human IVOC
We aimed to determine if intimin–Tir interaction is sufficient for A/E lesion formation on
mucosal surfaces. With this in mind, we infected human duodenal biopsies with EPEC1 or
EPEC2. WT EPEC and EPEC0 were used as positive and negative controls, respectively. After
7 h of infection, biopsies were washed, fixed and analyzed by scanning electron microscopy
(SEM). Inspection of the mucosal surface revealed A/E lesions in ca. 77% of the biopsies
infected with WT EPEC, whereas no A/E lesions were seen in IVOC infected with EPEC2,
EPEC1 or EPEC0 (Fig 5 and Table 2).
In order to control that mucus does not affect the interaction of EPEC2 and EPEC1 with
the cells and therefore the formation of A/E lesions, mucus-producing human colonic cells
LS174T (S7 Fig) were infected with EPEC2, EPEC1 and EPEC0. WT EPEC was used as a posi-
tive control. This revealed similar adhesion of bacterial microcolonies and formation of actin
found in the extracellular medium labeling the translocators EspABD and the autotransporter EspC. Molecular
standards are shown in kDa. Bottom panels: Western blots of bacterial whole-cell protein extracts incubated
with polyclonal antibodies to detect EscC, EscJ, EscD injectisome proteins and EspB translocator protein.
Detection of cytoplasmic GroEL was used as a loading control. Discontinuous lines indicate borders of
independent gels. B. Immunofluorescence confocal microscopy of HeLa cells infected for 90 min with WT
EPEC, EPEC2, EPEC1 and EPEC0 strains. EPEC bacteria are labeled with anti-intimin-280 polyclonal
(green), actin is labeled with TRITC-phalloidin (red) and cell nuclei are labeled with DAPI (gray). Actin
polymerization beneath the adherent bacteria is observed in EPECwt, EPEC2 and EPEC1 strains. Scale bar
5 μm. C. Quantification of the number of HeLa cells with actin pedestals after infection with the indicated
strains WT, EPEC2, EPEC1 and EPEC0. The data shown are the mean of two independent experiments with
standard deviation (SD). In each experiment, one hundred cells per infection sample were counted. D. Protein
translocation into HeLa cells of β-lactamase (Bla) fusion by EPEC effector mutants. HeLa cells were infected
for 90 min with the indicated EPEC strains (WT EPEC, EPECΔescN, EPEC2, EPEC1 EPEC0), expressing
EspF1-20-Bla fusion (WT EPEC, EPECΔescN, EPEC2, EPEC1, EPEC0) or the control vector pCX340, and
then incubated with the BLA substrate CCF2/AM for additional 1 h. Bla activity was quantified measuring the
emission ratio of fluorescence at 450/520 nm. Results are the mean of three independent experiments with
standard deviation (SD). One way ANOVA Tukey’s Multiple Comparison Test. **p<0.01 and ***p<0.001.
https://doi.org/10.1371/journal.ppat.1006706.g002
EPEC non-LEE effectors in A/E lesion formation
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Fig 3. Induction of filopodia by EPEC effector mutants with integrated map. Immunofluorescence
microscopy of Swiss 3T3 cells infected for 10 min with EPEC2, EPEC1 and EPEC0 and isogenic strains with
map integrated in the chromosome. EPEC was detected with rabbit polyclonal anti-O127 (red) and actin was
stained with Oregon-green phalloidin (green). Filopodia spikes are labelled with arrowheads. Actin
accumulation beneath bacteria is indicated with arrows. Scale bar 2 μm.
https://doi.org/10.1371/journal.ppat.1006706.g003
EPEC non-LEE effectors in A/E lesion formation
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pedestals by WT, EPEC2 and EPEC1 (S8 Fig). Hence, despite inducing actin pedestals in cul-
tured intestinal epithelial cells in vitro, EPEC1 and EPEC2 could not induce A/E lesions in
human intestinal tissue ex vivo, indicating that intimin-Tir interaction is necessary but not suf-
ficient and that additional effectors are needed.
As the LEE is universally conserved in clinical EPEC isolates we investigated if effectors
encoded on the LEE, other than Tir and EspZ, were required for A/E lesions in human intesti-
nal biopsies. For this, we infected IVOC with a derivative strain of EPEC2, called EPEC2LEE,
in which the genes espG, map, espF, and espH were reintegrated into their original locus on the
LEE. Infection with WT EPEC was used as a control. This revealed that EPEC2LEE was
severely impaired in its ability to form A/E lesions (Fig 5 and Table 2), as a single A/E lesion
was found in only one of the eleven biopsies infected by EPEC2LEE (Table 2). No adherent
bacteria were seen in all the other 10 IVOCs infected with EPEC2LEE (Fig 5). In addition, we
tested whether EPEC9, which expresses all non-LEE effectors and misses all LEE effectors
except EspZ and Tir, can trigger A/E lesions in IVOC. This revealed that EPEC9 induced A/E
lesions in biopsies at a comparable efficiency to WT EPEC (Fig 5 and Table 2). Taken together,
Fig 4. Translocation of NleC by EPEC effectors mutants induces p65 degradation. A. Western blot
detecting NF-κB p65 protein in HeLa cells infected for 4 h (1 h+3 h gentamicin) with EPEC2, EPEC1 and
EPEC0 and isogenic strains with nleC integrated in the chromosome. Uninfected (UI) cells and cells infected
with WT EPEC are used as controls. Detection of α-tubulin was used as a loading control. B. Quantification of
p65 in Hela cells infected with the indicated strains. Protein loading was normalized with α-tubulin. Results are
the mean of three independent experiments with standard deviation (SD). One way ANOVA Tukey’s Multiple
Comparison Test. **p <0.01; ***p <0.001.
https://doi.org/10.1371/journal.ppat.1006706.g004
EPEC non-LEE effectors in A/E lesion formation
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these results indicate that non-LEE effectors are important for A/E lesion formation by EPEC
in human intestinal tissue.
The role of Efa1/LifA homologs in A/E lesion formation ex vivo
To investigate the contribution of the non-LEE effectors to A/E lesion formation, we first ana-
lyzed the outcome of IVOC infection with EPEC8, EPEC7 and EPEC6. These strains are deriv-
atives of EPEC9 having sequential deletions of effectors genes present in IE5 (espG2, espC), IE6
(espL, nleB, nleE, efa1/lifA) and IE2 (espL, nleB, nleE2, efa1/lifA-like) (Table 1; Fig 1). EPEC8
Fig 5. A/E lesion formation in human intestinal biopsies infected with EPEC effector mutant strains.
Representative scanning electron micrographs of human duodenal biopsies infected with the indicated EPEC
strains. WT EPEC and EPEC9 strains induce the characteristic A/E lesions in the intestinal mucosal surface,
forming bacterial microcolonies (asterisk) and elongation of microvilli at the periphery of the microcolony
(arrowheads). Biopsies infected with EPEC2, EPEC1, EPEC0 show a smooth epithelial surface without any
adherent bacteria. Most biopsies infected by EPEC2LEE (10/11) also showed an intact mucosal surface
without bacteria. Scale bar 2 μm.
https://doi.org/10.1371/journal.ppat.1006706.g005
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formed A/E lesions at the same frequency as WT and EPEC9 (Tables 2 and 3). Deletion of IE6
alone (EPEC7) caused a reduction in the frequency of A/E lesions (54%), however this did not
reach significance. Moreover the proportion of biopsies with A/E lesions decreased signifi-
cantly 23% following infections with EPEC6 (Table 3). Together this suggest that IE6 and IE2
contribute to A/E lesion formation. Therefore, we investigated the contribution of individual
effectors found within IE2. IE2 carries the pseudogenes espL and nleB, as well as the effector
genes nleE2 and efa1/lifA-like. Therefore, we generated individual deletions of efa1/lifA-like
and nleE2 in EPEC7 (Table 1 and S9A Fig). We confirmed by RT-PCR that deletion of nleE2
has no polar effects on the expression of efa1/lifA-like in IE2, and viceversa (S9B Fig). Infection
of IVOC revealed that EPEC7ΔnleE2 (carrying a functional copy of efa1/lifA-like) induced A/E
lesion in 64% of the infected biopsies, similar to the parental EPEC7 strain (Table 3). In con-
trast, EPEC7Δefa1/lifA-like triggered A/E lesions in 33% of the infected biopsies (Table 3), sim-
ilar to EPEC6. These results show that deletion of efa1/lifA-like in EPEC7 has a significant
impact on A/E lesion formation.
To further investigate the potential role of LifA-like and LifA in EPEC A/E lesion forma-
tion, we generated single (EPECΔlifA-like and EPECΔlifA) and double (EPECΔlifA-like ΔlifA)
deletion mutants in WT EPEC (Table 1). These mutants secreted normal levels of EspA, EspB
and EspD (S10A Fig) and produced microcolonies and actin pedestals in HeLa cells similar to
Table 2. A/E lesions in human intestinal biopsies infected with EPEC effector mutants.
Strain Effector genes, IEs and PPs present A/E lesions
Positive/Total (%)
P value *
E2348/69 wild type 17/22 (77) a
EPEC2 espZ, tir 0/6 (0) 0.0012
EPEC1 tir 0/6 (0) 0.0012
EPEC0 none 0/11 (0) 0.0001
EPEC2LEE espZ, tir, map, espH, espF, espG 1/11 (9) b 0.0005
EPEC9 espZ, tir, IE5, IE6, IE2, PP2, PP3, PP4, PP6 9/11 (82) NS
Notes: (*) Two-tailed P values of Fisher’s exact test of indicated strain compared to the wild type. NS means not statistically significant (P values > 0.05)
aEPEC wt was used as a positive control in the experiments of Tables 2 and 3, which explains the higher number of biopsies infected with this strain.
bEPECLEE formed a single A/E lesion in one biopsy.
https://doi.org/10.1371/journal.ppat.1006706.t002
Table 3. A/E lesions formation by EPEC deletion mutants in IE effectors.
Strain Effectors genes, IEs and PPs present A/E lesions
Positive/Total (%)
P value *
E2348/69 Wild type 17/22 (77)
EPEC8 espZ, tir, IE6, IE2, PP2, PP3, PP4, PP6 10/14 (71) NS
EPEC7 espZ, tir, IE2, PP2, PP3, PP4, PP6 7/13 (54) NS
EPEC6 espZ, tir, PP2, PP3, PP4, PP6 3/13 (23) 0.0038
EPEC7ΔnleE2 espZ, tir, lifA-like, PP2, PP3, PP4, PP6 7/11 (64) NS
EPEC7ΔlifA-like espZ, tir, nleE2, PP2, PP3, PP4, PP6 4/12 (33) 0.0248
EPECΔlifA-like Wild type repertoire ΔlifA-like 5/6 (83) NS
EPECΔlifA Wild type repertoire ΔlifA 5/5 (100) NS
EPECΔlifA-like ΔlifA Wild type repertoire ΔlifA-like ΔlifA 5/6 (83) NS
EPEC0 none 0/11 (0) 0.0001
Notes: (*) Two-tailed P values of Fisher’s exact test of indicated strain compared to the wild type. NS means not statistically significant (P values > 0.05)
https://doi.org/10.1371/journal.ppat.1006706.t003
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the WT strain (S10B Fig). Interestingly, infection of human biopsies showed that A/E lesions
were formed at efficiencies similar to the WT strain by ΔlifA-like and ΔlifA single and double
mutant strains (Table 3 and S11 Fig). Collectively, these results indicate that non-LEE effectors
play a major role for A/E lesion formation on human intestinal tissue ex vivo, and suggest an
accessory role of LifA-like and LifA proteins in this process, which is masked in the presence
of the entire repertoire of T3SS effectors.
Discussion
EPEC is a major etiological agent of infant diarrhea [48, 49]. With the aim of defining the
T3SS effectors implicated in A/E lesion formation, we generated a library of mutants missing
part or the whole arsenal of effectors present in the prototypical strain E2348/69. We have
demonstrated that the marker-less genome edition strategy generated precise deletions and
gene integrations in EPEC. We have built the effector-less EPEC strain (EPEC0) devoid of all
known T3SS effectors through 13 deletions, 326 bp was the smallest deletion (espZ) and 18260
bp the largest deletion (IE6). The effector genes were deleted from the start to the stop codon,
maintaining their original transcriptional promoters and terminator signals. The only excep-
tion was the deletion of espZ, in which deletion of its RBS was necessary to maintain correct
expression of the T3SS apparatus.
The LEE effector genes espZ and tir were deleted last as they are important to control pro-
tein translocation and bacterial attachment to host cells [19, 35, 50]. Infection of cultured epi-
thelial cells with the WT EPEC and the effector mutant strains demonstrated the functionality
of the T3SS. Infection of HeLa and mucin-producing LS174T cells with EPEC2 (espZ and tir)
and EPEC1 (tir) showed accumulation of F-actin underneath the attached bacteria, confirming
that EPEC only needs the effector Tir to induce the actin-pedestals during infection of epithe-
lial cells in vitro. As expected, no pedestals were seen in cells infected with EPEC0.
Protein translocation assays indicated that all effector mutant strains, including EPEC0,
translocate EspF1-20-Bla fusion into HeLa cells, albeit at different efficiency. EPEC1 showed
the highest protein translocation level, likely due to absence of EspZ, which limits protein
translocation [19]. In contrast, EPEC0 showed the lowest level of protein translocation
owing to the absence of intimate adhesion [35, 50]. We have demonstrated that the EPEC
effector mutants provide an excellent tool to study the function of individual effectors,
under physiological expression levels, in an infection context as chromosomal single-copy
integrations reproduce phenotypes previously reported for Map (filopodia formation) and
NleC (NF-kB) degradation.
Importantly, using IVOC our study revealed that intimin–Tir interaction is not sufficient
for A/E lesion formation and that other effector(s) are needed, as no A/E lesions were observed
in biopsies infected with EPEC2 and EPEC1. Furthermore, infections of IVOC with EPE-
C2LEE (lacking all non-LEE effectors) and EPEC9 (expressing the whole non-LEE repertoire
of effectors plus EspZ and Tir), showed that A/E lesion formation requires Tir and EspZ and
non-LEE effectors. The difference in effector requirement for intimate adhesion of bacteria in
cultured cells (Tir) and A/E lesion in intestinal tissue (Tir+non-LEE) might be due to a more
stringent requirement for a productive interaction of bacteria with a complex tissue surface
and/or for the hijack of cellular functions in intestinal tissue.
We further characterized the contribution of specific non-LEE effectors to A/E lesion for-
mation by performing IVOC with mutant strains having sequential deletion of non-LEE effec-
tor genes. These experiments showed a dramatic reduction of A/E lesion formation when IE6
and, especially, IE2 are deleted (EPEC6). IE6 (espL, nleB1, nleE1 and efa1/lifA) and IE2 (espL,
nleB, nleE2 and efa/lifA-like) encode a similar set of effectors. We reasoned that either nleE2
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or efa1/lifA-like effectors of IE2 should play a role in A/E lesion formation. Albeit NleE2 in IE2
has an internal deletion of 56 residues that could impede its translocation or function [51], we
generated EPEC7ΔlifA-like and EPEC7ΔnleE2 mutants. We found that EPEC7ΔlifA-like strain,
but not the EPEC7ΔnleE2 strain, exhibited a reduced efficiency of A/E lesion formation to val-
ues close to those of EPEC6, suggesting that Efa1/LifA-like protein plays a role in A/E lesion
formation ex vivo in the effector mutants.
Efa-1/LifA-like protein was identified in the genome of EPEC E2348/69 as a homolog with
aprox. 30% amino acid identity with Lymphostatin (LifA), encoded in IE6 [20]. The lifA gene,
for lymphocyte inhibitory factor A, was first described in EPEC as a chromosomally encoded
protein of 365 kDa that inhibits proliferation of lymphocytes and the synthesis of proinflam-
matory cytokines [26, 29]. LifA was later shown to be secreted and translocated into mamma-
lian cells in a T3SS-dependent manner [25]. Efa-1/LifA-like homolog is also secreted in a
T3-dependent manner by EPEC, but there is no evidence of its translocation into mammalian
cells [25]. LifA homologs are found exclusively in the genomes of A/E pathogens[27–29].
Interestingly, efa1/lifA has been found physically linked to the LEE in some EHEC and EPEC
strains [52]. In EHEC, EPEC, and C. rodentium, LifA/Efa-1 has been associated to cell adhe-
sion and tissue colonization [28, 53–55]. In addition, LifA/Efa-1 proteins have been implicated
in the induction of intestinal barrier disruption by manipulation of cellular Rho GTPases [56].
While playing a role in A/E lesion formation efficiency, our data show that these proteins are
not essential for this process. EPEC6 and EPEC7ΔlifA-like strains still induce A/E lesion for-
mation in 23–33% of infected biopsies (Table 3). Moreover, EPECΔlifA-likeΔlifA behaves as
the WT strain forming actin-pedestals on epithelial cells in vitro and A/E lesions on human
intestinal tissue ex vivo. Thus, the efa1/lifA-like proteins have an accessory role in A/E lesion
formation, which is masked by other T3SS effectors found in the repertoire of the WT strain.
These evidences suggest that Ea1/lifA-like protein could act in the subversion of some cellular
functions needed for the establishment of the A/E lesion, but its activity can be exerted by
alternative EPEC effectors found in the wild type repertoire. This fact also strengthens our
experimental approach in which the role of effectors should be better analyzed in the context
of infection with strains expressing a reduced and defined set of effectors, since the WT EPEC
strain may have multiple effectors with overlapping, synergistic and/or antagonistic effects.
The role and molecular mechanism of Efa/LifA homologs in A/E lesion formation requires
further investigation.
In summary, our study shows that intimin–Tir is not sufficient for A/E lesion formation in
human intestinal mucosal tissue and other effectors are needed. EPEC expressing only the LEE
effectors rarely produces A/E lesions, indicating that non-LEE effectors play a major role in
this process, having an additive role the effectors encoded in the IE2, IE6 and PPs.
Methods
Bacterial strains and growth conditions
The EPEC strains used in this work are listed in Table 1. E. coli K-12 strains used for cloning
are listed in Table A of S1 Text. Bacteria were grown in Luria-Bertani (LB) liquid medium and
agar-plates (1.5% w/v) or in Dulbecco’s Modified Eagle Medium (DMEM), at 37 oC, unless
otherwise indicated. When needed for plasmid or strain selection, antibiotics were added at
the following concentrations: ampicillin (Amp) at 150 μg/ml for plasmid selection, and at
75 μg/ml for selection of Amp resistance cassette in the chromosome; chloramphenicol (Cm)
30 μg/ml; kanamycin (Km) 50 μg/ml; tetracycline (Tc) 10 μg/ml; spectinomycin (Sp) 50 μg/ml.
See S1 Text for details.
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Plasmids, DNA constructs, and primers
The plasmids employed in this study are listed in Table A of S1 Text. PCRs were performed
with the Taq DNA polymerase (Roche, NZyTech) for standard amplifications in screenings or
with the proof-reading DNA polymerases Herculase II Fusion (Agilent Technologies) or Vent
DNA polymerase (NEB) for cloning purposes. When indicated, DNA was synthesized by Gen-
eArt (Life Technologies). All DNA constructs were confirmed by DNA sequencing (Secugen
and Macrogen). Oligonucleotides used in this work were obtained from Sigma and are
described in Table C of S1 Text.
EPEC genome modifications and construction of strains
A summary of genome modifications and construction of EPEC strains are listed in Table B of
S1 Text. Site-specific deletions and insertions in the chromosome of EPEC were originated
using a marker-less genome edition strategy with I-SceI [34]. The EPEC strain to be modified
was initially transformed with a plasmid pACBSR (CmR) or its SpR-variant pACBSR-Sp [57],
both expressing the I-SceI and λ-Red proteins under the control of the PBAD promoter. Subse-
quently, these bacteria were electroporated with the corresponding pGE-based or pGETS- vec-
tor (KmR) and plated on LB-Km-(Cm or Sp). Selection of individual KmR-cointegrants and
their resolution upon induction with L-arabinose for isolation of the strains with mutant alleles
are described in detail in the S1 Text. All EPEC strains generated were cured of pACBSR
before their analysis by serial passages on LB media lacking antibiotics and selection of Cm- or
Sp-sensitive colonies. All EPEC strains were confirmed by PCR with specific primers (Tables B
and C of S1 Text).
Genome sequencing and analysis
The genomes of EPEC1 and the parental EPEC WT strains were sequenced on an Illumina
Miseq platform. Average reads length between 150 and 174 bases and the global coverage was
>100X. Genomes were assembled de novo and using reference-guided assemblies with the
genome sequence of EPEC O127:H6 strain E2348/69 (nc_011601) and the in silico-designed
reference sequence of EPEC1, as described in the S1 Text. The accession number of the
genome sequence of EPEC1 effector mutant strain is<PRJEB18717>, and that of the parental
EPEC WT strain E2348/69 is<PRJEB18716>. These genome sequences are available at the
’European Nucleotide Archive’ http://www.ebi.ac.uk/ena/data/view/<ACCESSION.
NUMBERS>.
SDS-PAGE and Western blot
Sodium Dodecyl Sulfate–Polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot
were performed as reported previously [58]. Preparation of EPEC protein extracts are
described in the S1 Text. For detection of EPEC proteins by Western blotting, membranes
were incubated with primary rabbit antibodies anti-EspB (1:2000), anti-EscC (1:1000), anti-
EscJ (1:5000), anti-EscD (1:1000) and anti-Intimin280 (1:5000). Use of polyclonal rabbit sera
against EPEC Intimin-280, EscC and EscD were described previously [57, 59]. Rabbit poly-
clonal serum against EscJ and EspB was a kind gift of Dr. Bertha Gonza´lez-Pedrajo (UNAM,
Mexico). Bound rabbit antibodies were detected with secondary Protein A-peroxidase (POD)
conjugate (Life Technologies, 1:5000). GroEL was detected with mAb anti-GroEL-POD conju-
gate (1:5000; Sigma). Membranes were developed by chemiluminiscence using the Clarity
Western ECL Substrate kit (Bio-Rad). The membranes were then developed by exposure to
X-ray films (Agfa) or with a Fuji LAS 3000 image when the signal was quantified.
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Infection of cell cultures and fluorescence confocal microscopy
Complete description of infection conditions and microscopy is described in the S1 Text.
Human HeLa cervix carcinoma cells (ATCC, CCL-2) were grown in DMEM supplemented
with 10% heat-inactivated fetal bovine serum (FBS; Sigma) and 2 mM glutamine, at 37 oC with
5% CO2. HeLa cells were washed once with pre-heated serum-free DMEM 2 h before the
infection, and infected with EPEC strains for 90 min using a multiplicity of infection (MOI) of
200:1, unless indicated otherwise. Infections were stopped by three washes of sterile PBS
(sigma), fixed with 4% (w/v) paraformaldehyde (in PBS, 20 min, RT) and washed again with
PBS. Cells were permeabilized by incubation in a solution of 0.1% (v/v) of saponin (Sigma) in
PBS for 10 min and washed with PBS. To stain EPEC strains, bacteria were incubated with
polyclonal rabbit anti-intimin280 (1:500), or anti-O127 (1:100) for Δeae mutants, and goat
anti-rabbit secondary antibodies conjugated to Alexa488 (1:500, Life technologies) in PBS with
10% goat serum; along with Phalloidin TRITC (1:500; Sigma) and 4’,6-diamidino-2-phenylin-
dole DAPI (1:1000; Sigma) to label F-actin and DNA and mounted with 4 μl of ProLong Gold
anti-fade reagent (Life technologies). To analyze translocation of NleC, HeLa cells were
infected 1 h and then washed three times with PBS and incubated for additional 3 h with
200 μg/ml of gentamicin in DMEM. Cells were washed with PBS to remove unbound bacteria
and cellular protein extracts were prepared analyzed by Western blot.
To analyze filopodia formation, infection with EPEC strain was done in Swiss 3T3 mouse
fibroblasts (ATCC; CCL-92) cells grown in DMEM-high glucose (D5671; Sigma) supple-
mented with 10% of heat-inactivated fetal calf serum (FCS; Sigma), 2 mM glutamine and 1X of
MEM non-essential amino acid solution 100X (Sigma). Swiss 3T3 cells were washed three
times with sterile pre-warmed PBS (Sigma) and serum-free DMEM 2 h previous to the infec-
tion. Infections were done with 500 μl of EPEC cultures grown in DMEM during 3 h (aprox.
MOI 500:1). The plates were centrifuged to synchronize the infection (500xg, 5 min, in a rotor
pre-warmed at 37 oC) and the infection was continued for additional 5 min. Infections were
stopped by three washes with sterile PBS (Sigma), fixed with 4% (w/v) paraformaldehyde (in
PBS, 20 min, RT) and washed with PBS. Fixed monolayers were incubated with polyclonal rab-
bit anti-O127 (1:100) and secondary donkey anti-rabbit-Alexa488 (Jackson ImmunoResearch,
1:100), together with Oregon-green Phalloidin (1:100, Invitrogen) to label bacteria and actin
respectively. Coverslips were washed 3 times with PBS after incubation and mounted with Pro-
Long Gold anti-fade reagent (Life technologies).
LS174T colon adenocarcinoma cells (ECACC 87060401) were grown in DMEM supple-
mented with 10% heat-inactivated fetal bovine serum (FBS; Sigma), 2 mM glutamine and 1X
of non-essential amino acids (Sigma) at 37 oC with 5% CO2. LS174T cells were washed three
times with pre-heated PBS (Sigma) 2 h before the infection. The cells were infected with 200 μl
(MOI ca. 200:1) for 90 min with EPEC grown in DMEM at 37 oC as described for HeLa cells
infections. Following washes with PBS (Sigma), the cells were fixed with 4% (w/v) paraformal-
dehyde (in PBS, 20 min, RT), washed again with PBS and permeabilized with 0.1% of Triton
X-100 (Sigma) in PBS for 10 min. The immunofluorescence staining of intimin, F-actin and
cell nuclei was done described previously for infections of HeLa cells. Mucin produced by
LS174T cells was stained with an anti-MUC2 rabbit-polyclonal antibody (1:250 Santa Cruz
biotechnology) and goat anti-rabbit IgG conjugated to Alexa488 (1:500, Life technologies) as
secondary Ab.
β-Lactamase translocation assay
β-lactamase (Bla) translocation was quantified as reported previously [43, 44] using LiveBLA-
zer FRET-B/G Loading Kit with CCF2-AM (ThermoFisher Scientific). Plates were read in a
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SpectraMax M2 fluorometer (Molecular Devices) with a filter set 450/520 nm. See S1 Text for
details.
Ethics statement
This study was performed with approval from the University of East Anglia Faculty of Medi-
cine and Health Ethics Committee (ref 2010/11-030). All samples were registered with the
Norwich Biorepository (NRES ref 08/h0304/85+5). Biopsy samples from the second part of the
duodenum were obtained with informed consent during upper endoscopy of adult patients at
the Norfolk and Norwich University Hospital. All samples were anonymized.
Infection of human intestinal biopsies and scanning electron microscopy
(SEM)
Up to 6 biopsy samples per donor were taken from macroscopically normal areas. Samples
were cut in half and infected with EPEC wildtype and mutant strains in duplicate. Each bacte-
rial strain was examined in human IVOC on at least three occasions using tissues from differ-
ent donors. IVOC was performed as described previously [30, 60]. Briefly, biopsies were
mounted on foam supports in 12 well plates and incubated with 25 μl standing overnight cul-
ture (approximately 107 bacteria). Samples were incubated for 7 h on a rocking platform at
37˚C in a 5% CO2 atmosphere. At the end of the experiment, tissues were fixed in 2.5% glutar-
aldehyde in PBS, dehydrated through a graded acetone series, and dried using tetramethylsi-
lane (Sigma). Samples were blinded and examined in a scanning electron microscope (Jeol
JSM-6390). Biopsies showing at least one A/E lesion were scored as positive.
RT-PCR to evaluate efa1/lifA-like and nleE2 gene expression
RNA was extracted from the EPEC strains and reversed transcribed by RT-PCR as described
previously [61]. The primers used for the RT-PCR of lifA-like, nleE2 and tir are listed in
Table C of S1 Text as 108 to 113.
Statistics
Mean and standard errors of experimental values were calculated with using Prism 5.0
(GraphPad software Inc). Statistical analyses comparing the mean of paired experimental
groups were conducted with Student’s t-test using Prism 5.0 (GraphPad software Inc). Sta-
tistical analyses comparing the number of A/E-positive and negative biopsies after infection
with the indicated EPEC strains were conducted with Fisher’s exact test to determine two-
tailed P values using Prism 5.0 (GraphPad software Inc). Data were considered significantly
different when p-values <0.05.
Supporting information
S1 Text. Supporting methods, tables A to D, and supplementary references.
(PDF)
S1 Fig. Markerless gene deletion strategy of EPEC effector genes. Deletions were carried out
by a markerless strategy using suicide plasmids with I-SceI sites and mutant alleles assembled
by fusing homology regions (HRs) flanking the targeted effector gene(s). Derivatives of pGE-
vector contain an R6K replication origin (π protein dependent) whereas derivatives of pGETS
contain a thermo-sensitive replication origin ori101 that replicates at 30˚C but not at 37–42˚C.
The lack of π protein in EPEC, or growth at non-permissive temperature, induce integration
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of the suicide vector in the chromosome. Co-integrants are identified by the Km resistance
phenotype. Expression of the I-SceI in vivo from helper plasmid induces double strand brakes
that are repaired by homologous recombination. Depending on the HRs involved in this sec-
ond recombination, either the WT or the mutant allele can be obtained. Mutants are selected
by PCR screening. Mutants do not carry any antibiotic gene marker, vector or recombination
sequences ("scars").
(TIF)
S2 Fig. Proteins secreted by EPEC WT and escN mutant generated by marker-less gene
deletion strategy. A. Schematic representation of EPEC T3SS injectisome, indicating the fila-
ment of EspA, the translocator proteins EspB and EspD, and the ATPase EscN. Secretion of
the autotransporter EspC is also shown. B. Coomassie staining of secreted proteins in extracel-
lular media of EPECΔescN and EPEC WT strains grown 4 h at 37˚C in DMEM. The transloca-
tors EspABD and the autotransporter EspC proteins are labeled. Molecular standards mass
proteins are shown in kDa.
(TIF)
S3 Fig. Generation of ΔespZ mutant allele with wild-type levels of T3SS. A. Schematic repre-
sentation of gene organization of espZ and escI, indicating the ribosome binding sites (RBS) in
the LEE2 operon of the EPEC WT strain and ΔespZ-1 and ΔespZ-2 mutant alleles. B. Coomassie
staining of proteins secreted in the extracellular media of EPECΔescN, EPEC WT, EPECΔespZ-
1 and EPECΔespZ-2 strains grown 4 h in DMEM at 37 oC. The translocators EspABD and the
autotransporter EspC are labeled. Molecular standards mass proteins are shown in kDa.
(TIF)
S4 Fig. PCR to confirm deletions of effectors in EPEC0. Agarose gel electrophoresis of PCR
products amplified from EPEC WT and EPEC0 strains using primers to check deletions
described in Tables B and C of S1 Text. The lanes corresponding to a deletion of an effector
gene or gene cluster are indicated on top. The order of the deletions is also numbered on top.
DNA bands corresponding to amplicons from IE5, IE6, IE2, PP4 and PP6, in the EPEC WT
strain are not visible given their poor amplification due to their large size. DNA markers are
labeled on the left (in bp).
(TIF)
S5 Fig. Growth, viability and morphology of EPEC effector mutant strains. A. Growth
curves of EPEC WT, EPEC2, EPEC1 and EPEC0 strains in LB following the optical density
(OD) at 600nm at the indicated times points. B. Bacterial viability (CFU/OD600) of the indi-
cated strains (EPEC WT, EPEC2, EPEC1 and EPEC0) grown in DMEM 4 h and plated in LB-
agar. C. Immunofluorescence microscopy of bacteroa from EPEC WT, EPEC2, EPEC1 and
EPEC0 strains stained with anti-intimin-280 polyclonal serum (green). Scale bar 2 μm.
(TIF)
S6 Fig. Deletion of eae in EPEC2 and EPEC1 strains. A. Top panel: Coomassie staining of
proteins secreted in the extracellular media by EPEC WT, EPEC2Δeae and EPEC1Δeae grown 4
h in DMEM at 37˚C. The translocators EspABD and the autotransporter EspC are labeled. Pro-
tein standards are labelled in kilodaltons (kDa). Bottom panels: Western blots of bacterial lysates
detected with rabbit polyclonal anti-intimin-280 and GroEL (as loading control). B. Immuno-
fluorescence confocal microscopy of HeLa cells infected 90 min with EPEC2, EPEC2Δeae,
EPEC1 and EPEC1Δeae. EPEC bacteria are labeled with anti-E. coli (green). Actin is labeled
with TRITC phalloidin (red) and cell nuclei are labeled with DAPI (gray). Scale bar 5 μm.
(TIF)
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S7 Fig. Mucin-2 staining of mucus-producing LS174T cells and mucus-deficient HeLa
cells. Immunofluorescence microscopy of LS174T and HeLa cells stained with anti-MUC2
rabbit-polyclonal antibody (green) and cell nuclei labeled with DAPI (gray). Scale bar 20 μm.
(TIF)
S8 Fig. Infection of human intestinal LS174T cells by EPEC WT and effector mutant
strains. Immunofluorescence confocal microscopy of LS174T cells infected for 90 min with
WT EPEC, EPEC2, EPEC1 and EPEC0. EPEC bacteria are labeled with anti-intimin-280 poly-
clonal serum (green), actin is labeled with TRITC-phalloidin (red) and cell nuclei are labeled
with DAPI (gray). Actin polymerization beneath the adherent bacteria is observed in WT
EPEC, EPEC2 and EPEC1 strains. Scale bar 10 μm.
(TIF)
S9 Fig. Deletion of nleE2 and efa1/lifA-like in EPEC7. A. Clusters of effectors in IE5, IE6 and
IE2. Red bars indicated deletion of IE5 and IE6 encoded-effectors and individual deletion of
nleE2 or lifA-like in EPEC7ΔnleE2 and EPEC7ΔlifA-like, respectively. B. Agarose gel electro-
pheresis of RT-PCR products of expression of lifA-like and nleE2 in effectors mutant strains.
EPEC7ΔlifA-like strain has normal expression of nleE2. EPEC2ΔnleE2 has normal expression
of lifA-like. EPEC7 has expression of lifA-like and nleE2. EPEC6 does not have expression of
lifA-like and nleE2. The expression of tir was used as a control for RT-PCR.
(TIF)
S10 Fig. Functionality of T3SS and infection of HeLa cells by deletion mutants in efa1/lifA
and efa1/lifA-like genes. A. Coomassie staining of proteins secreted in the extracellular
medium in the indicated EPEC strains grown in DMEM at 37 oC. Protein bands correspond-
ing to the translocators EspA, EspB, EspD and the autotransporter EspC are labelled. Molecu-
lar standards are shown in kDa B. Immunofluorescence confocal microscopy of HeLa cells
infected for 90 min with WT EPEC, EPECΔescN, EPECΔlifA-like, EPECΔlifA and EPECΔlifA-
likeΔlifA strains. EPEC bacteria are labeled with anti-intimin-280 polyclonal serum (green),
actin is labeled with TRITC-phalloidin (red) and cell nuclei are labeled with DAPI (gray).
Actin polymerization beneath adherent bacteria is observed in WT EPEC, EPECΔlifA-like,
EPECΔlifA and EPECΔlifA-likeΔlifA. Scale bar 10 μm.
(TIF)
S11 Fig. A/E lesion formation in human intestinal biopsies infected with EPEC ΔlifA and
ΔlifA-like mutant strains. Scanning electron micrographs of human duodenal biopsies
infected with EPECΔlifA-like, EPECΔlifA, and double mutant EPECΔlifA-likeΔlifA, showing
A/E lesions formed in the intestinal mucosal surface. Large bacterial microcolonies (asterisk)
and elongation of microvilli at the periphery of the microcolony (arrowheads) are labeled.
Scale bar 5 μm.
(TIF)
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